Navigation Links
Ecstasy could help patients with post-traumatic stress disorder
Date:3/8/2009

Los Angeles, London, New Delhi, Singapore and Washington DC (March 9th, 2009) Ecstasy may help suffers of post-traumatic stress learn to deal with their memories more effectively by encouraging a feeling of safety, according to an article in the Journal of Psychopharmacology published today by SAGE.

Studies have shown that a type of psychological treatment called exposure therapy where the patient repeatedly recalls the traumatic experience or is repeatedly exposed to situations that are safe but still trigger their traumatic feelings can be effective in relieving stress responses in patients with post-traumatic stress disorder (PTSD) and other anxious conditions. The therapy works by helping the patient to re-learn the appropriate response to the trigger situation, a process known as extinction learning.

But this approach can take some time, and 40% of patients continue to experience post-traumatic stress even after their treatment. To improve outcomes, scientists have been investigating the use of drug therapies to enhance the effect of exposure therapy, making the result of exposure to the fear trigger easier, faster, and more effective. MDMA (the pharmaceutical version of Ecstasy) is one such drug.

"A goal during exposure therapy for PTSD is to recall distressing experiences while at the same time remaining grounded in the present. Emotional avoidance is the most common obstacle in exposure therapy for PTSD, and high within-session emotional engagement predicts better outcome," explain authors Pl-rjan Johansen and Teri Krebs, who are based at the Norwegian University of Science and Technology and supported by the Research Council of Norway.

Psychiatrists that have administered MDMA to anxiety patients have noted that it promotes emotional engagement; strengthens the bond between the patient and doctor, known as the therapeutic alliance; decreases emotional avoidance; and improves tolerance for recall and processing of painful memories.

According to Johansen and Krebs, "MDMA [ecstasy] has a combination of pharmacological effects thatcould provide a balance of activating emotions while feeling safe and in control."

They suggest three possible biological reasons why ecstasy could help individuals with PSTD. First, ecstasy is known to increase the release of the hormone oxytocin, which is involved in trust, empathy, and social closeness.

Because people with PTSD often report feeling emotionally disconnected and unable to benefit from the supportive presence of family and friends or therapists a situation that is likely to contribute to the development and maintenance of the disorder use of ecstasy might also help ameliorate these symptoms, suggest the authors.

"By increasing oxytocin levels, MDMA may strengthen engagement in the therapeutic alliance and facilitate beneficial exposure to interpersonal closeness and mutual trust," they write.

The second biological explanation for ecstasy's useful effect is that it acts in two brain regions to inhibit the automatic fear response (mediated by the amygadala) and increase emotional control (mediated by the ventromedial prefrontal cortex) and therefore permits bearable revisiting of traumatic memories.

Thirdly, ecstasy increases the release of two other hormones, noradrenaline and cortisol, which are known to be essential to trigger emotional learning, including the process that leads to fear extinction, on which therapy for PTSD relies. But, caution the authors, while these compounds enhance extinction learning they may also temporarily increase anxiety in people with PTSD because the hormones are naturally released as part of the body's response to stress.

Ecstasy combined with psychotherapy is a treatment already being tested in clinical trials to help patients with PTSD. All of these trials have a similar design in which ecstasy or placebo is administered to patients a few times during their therapy sessions as part of a short term course of psychological treatment. According to the Johansen and Krebs, recent preliminary results from two of these randomized controlled trials shows that the therapy might have promise.

"Reduction of avoidance behavior linked to emotions is a common treatment target for all anxiety disorders. MDMA [ecstasy] has a combination of pharmacological effects that, in a therapeutic setting, could provide a balance of activating emotions while feeling safe and in control, as has been described in case reports of MDMA augmented psychotherapy.Future clinical trials could combine MDMA with evidence-based treatment programs for disorders of emotional regulation, such as prolonged exposure therapy for PTSD," conclude the authors.


'/>"/>

Contact: Mithu Mukherjee
mithu.mukherjee@sagepub.co.uk
44-020-732-42223
SAGE Publications UK
Source:Eurekalert

Related medicine news :

1. Study provides hope that some transplant patients could live free of antirejection drugs
2. Study provides hope that some transplant patients could live free of anti-rejection drugs
3. HIV denialists spread misinformation online -- consequences could be deadly; and more
4. Virus Could Help Drive Obesity
5. Discovery of sugar sensor in intestine could benefit diabetes
6. Cranberry Could Juice Up Ovarian Cancer Treatment
7. Treating Diabetes During Pregnancy Could Lead to Thinner Kids
8. High-risk behaviors could lead to HIV epidemic in Afghanistan
9. Chinas 1-child policy could backfire on its elderly
10. 1.5 million children could be saved
11. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... ... Early this week, Team Iconic at J. Walter Thompson and Nestlé KITKAT ... global confectionery brand sourced from 100% sustainable cocoa. , The Nestlé Cocoa Plan aims ... activities that focus on better farming, better lives and better cocoa. In order to ...
(Date:2/10/2016)... PA (PRWEB) , ... February 10, 2016 , ... As ... offer two webinars in February 2016. Each webinar features a dynamic expert and ... to benefit their athletes, patients and facilities. Both events are free to attend, ...
(Date:2/10/2016)... ... ... Emergency rooms provide emergency care to stabilize critical health issues, but emergency ... emergencies at risk of losing a tooth or their smiles. Dr. Marine Martirosyan, ... emergencies include:, , Avulsed or knocked-out teeth , ...
(Date:2/10/2016)... St. Louis, Missouri (PRWEB) , ... February 10, ... ... 11-14, 2016, in San Diego, will bring together more than 200 of the ... in healthcare for the future. , “The true benefit of the Forum is ...
(Date:2/10/2016)... ... ... AHRA: The Association for Medical Imaging Management announced today ... as keynote speaker at the organization’s 2016 Spring Conference. Fox’s topic, Lead with ... with their own organizational staff and leadership. , “I am so excited ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)...  The ALS Association, in partnership with ALS Finding a ... a biomarker to track TDP43 aggregation. The successful team(s) with ... million investment. --> --> ... cells in the brain and the spinal cord. Eventually, people ... movement, which often leads to total paralysis and death within ...
(Date:2/10/2016)... 2016 Puerto Rico Healthcare and Life ... Healthcare and Life Sciences Report 2016 . --> ... Rico Healthcare and Life Sciences Report 2016 . ... largest territory in the world for pharma manufacturing, a territory ... manufacturing, and more universities per square mile than anywhere else ...
(Date:2/10/2016)... 2016  Visage Imaging Inc. ("Visage"), a wholly ... announced that the American College of Radiology (ACR) ... the Visage 7 Enterprise Imaging Platform as the ... Imaging SIMulation (SIM). SIM is the assessment component ... a multi-faceted and fully-integrated online assessment, education and ...
Breaking Medicine Technology: